2,480
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole‒clove oil transferosomal nanoparticles

, , , , ORCID Icon, , & show all
Pages 2229-2240 | Received 26 Aug 2021, Accepted 04 Oct 2021, Published online: 20 Oct 2021

References

  • Abou-Taleb HA, Khallaf RA, Abdel-Aleem JA. (2018). Intranasal niosomes of nefopam with improved bioavailability: preparation, optimization, and in-vivo evaluation. Drug Des Devel Ther 12:3501–16.
  • Ahmed OAA, Kurakula M, Banjar ZM, et al. (2015). Quality by design coupled with near infrared in formulation of transdermal glimepiride liposomal films. J Pharm Sci 104:2062–75.
  • Alghaith AF, Alshehri S, Alhakamy NA, Hosny KM. (2021). Development, optimization and characterization of nanoemulsion loaded with clove oil-naftifine antifungal for the management of tinea. Drug Deliv 28:343–56.
  • Alhakamy NA, Badr-Eldin SM, A Fahmy U, et al. (2020). Thymoquinone-Loaded Soy-phospholipid-based phytosomes exhibit anticancer potential against human lung cancer cells. Pharmaceutics 12:761.
  • Alkhalidi HM, Naguib GH, Kurakula M, et al. (2018). In vitro and preclinical assessment of factorial design based nanoethosomal transdermal film formulation of mefenamic acid to overcome barriers to its use in relieving pain and inflammation. J Drug Deliv Sci Technol 48:450–6.
  • Anwar M, Muhammad F, Akhtar B, et al. (2020). Nephroprotective effects of curcumin loaded chitosan nanoparticles in cypermethrin induced renal toxicity in rabbits. Environ Sci Pollut Res Int 27:14771–9.
  • Baldisserotto B, Parodi TV, Stevens ED. (2018). Lack of postexposure analgesic efficacy of low concentrations of eugenol in zebrafish. Vet Anaesth Analg 45:48–56.
  • Bellmann R, Smuszkiewicz P. (2017). Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:737–79.
  • Buss N, Snell P, Bock J, et al. (2001). Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 52:255–64.
  • Cao SL, Ren XW, Zhang QZ, et al. (2009). In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm 365:109–15.
  • Cevc G, Blume G. (2003). Biological activity, and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. Biochim Biophys Acta 1614:156–64. 7
  • Chakrabarti A, Das A, Panda NK. (2009). Controversies surrounding the categorization of fungal sinusitis. Med Mycol 47:S299–S308.
  • Chris Rathbun R, Hoffman HL. (2002). Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11:409–29.
  • Darvishi E, Omidi M, Bushehri AAS, et al. (2013). The antifungal eugenol perturbs dual aromatic and branched-chain amino acid permeases in the cytoplasmic membrane of yeast. PLoS One 8:e76028.
  • Dervis E, Yurt Kilcar A, Medine EI, et al. (2017). In vitro incorporation of radioiodinated eugenol on adenocarcinoma cell lines (Caco2, MCF7, and PC3). Cancer Biother Radiopharm 32:75–81.,
  • El Maghraby GM, Williams AC, Barry BW. (2000). Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm 196:63–74. 25
  • El-Emam GA, Girgis GNS, El-Sokkary MMA, et al. (2020). Ocular inserts of voriconazole-loaded proniosomal gels: formulation, evaluation and microbiological studies. Int J Nanomedicine 15:7825–40.
  • Galgatte UC, Kumbhar AB, Chaudhari PD. (2014). Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv 21:62–73.
  • Guo J, Ping Q, Sun G, Jiao C. (2000). Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 194:201–7.
  • Gupta A, Aggarwal G, Singla S, Arora R. (2012). Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline, development, characterization, and performance evaluation. Sci Pharm 80:1061–80.
  • Hamed SF, Sadek Z, Edris A. (2012). Antioxidant and antimicrobial activities of clove bud essential oil and eugenol nanoparticles in alcohol-free microemulsion. J Oleo Sci 61:641–8.
  • Herbrecht R. (2004). Voriconazole: therapeutic review of a new azole antifungal. Expert Rev anti Infect Ther 2:485–97.
  • Hosny KM, Alhakamy NA, Sindi AM, Khallaf RA. (2020). Coconut oil nanoemulsion loaded with a statin hypolipidemic drug for management of burns, formulation and in vivo evaluation. Pharmaceutics 7:1061.
  • Hosny KM, Alhakamy NA. (2020). Nasal gel loaded with amphotericin nanotransferosomes as antifungal treatment for fungal sinusitis. Pharmaceutics 13:35.
  • Hosny KM, Rizg WY, Khallaf RA. (2020). Preparation and optimization of in situ gel loaded with rosuvastatin-ellagic acid nanotransfersomes to enhance the anti-proliferative activity. Pharmaceutics 12:263.
  • Hosny KM, Sindi AM, Alkhalidi HM, et al. (2021). Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain. Drug Deliv 28:741–51.
  • Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. (2003). Voriconazole. Clin Ther 25:1321–81.
  • Jogani V, Jinturkar K, Vyas T, Misra A. (2008). Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul 2:25–40.
  • Khajeh M. (2009). Application of Box-Behnken design in the optimization of a magnetic nanoparticle procedure for zinc determination in analytical samples by inductively coupled plasma optical emission spectrometry. J Hazard Mater 172:385–9. 15
  • Khallaf RA, Aboud HM, Sayed OM. (2020). Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation. J Liposome Res 30:163–73.
  • Kim SS, Oh OJ, Min HY, et al. (2003). Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264. 7 cells. Life Sci 73:337–48.
  • Laverdiere M, Bow EJ, Rotstein C, et al. (2014). Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol 25:327–43.
  • Lee SJ, Han JI, Lee SHG, et al. (2007). Antifungal effect of eugenol and nerolidol against microsporum gypseum in a guinea pig model. Biol Pharm Bull 30:184–8.
  • Maertens JA, Raad II, Marr KA, et al. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387:760–9. 20
  • Maheshwari RG, Tekade RK, Sharma PA, et al. (2012). Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J 20:161–70.
  • Mahtab A, Anwar M, Mallick N, et al. (2016). Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech 17:1477–90.
  • Miranda-Cadena K, Marcos-Arias C, Mateo E, et al. (2018). Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. Arch Oral Biol 95:100–7.
  • Montone KT. (2014). Recent considerations in the classification and pathogenesis of fungal rhinosinusitis. In: pathobiology of human disease, a dynamic encyclopedia of disease mechanisms. Amsterdam, The Netherlands: Elsevier. pp. 1432–44.
  • Montone KT. (2016). Pathology of fungal rhinosinusitis: a review. Head Neck Pathol 10:40–6.
  • Mutalik S, Udupa N. (2003). Effect of some penetration enhancers on the permeation of glibenclamide and glipizide through mouse skin. Pharmazie 58:891–4.
  • Patra JK, Das G, Fraceto LF, et al. (2018). Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 16:71.
  • Qushawy M, Nasr A, Abd-Alhaseeb M, Swidan S. (2018). Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics 10:26.
  • Raju YP, Hyndavi N, Chowdary VH, et al. (2017). In vitro assessment of non-irritant microemulsified voriconazole hydrogel system. Artif Cells Nanomed Biotechnol 45:1539–47.
  • Rençber S, Karavana SY. (2018). Development and in vitro evaluation of voriconazole nanoparticle formulation for mucosal application. Turk J Pharm Sci 15:142–8.
  • Salem HF, El-Menshawe SF, Khallaf RA, Rabea YK. (2020). A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension, optimization using Box-Benkhen design, in vitro and in vivo characterization. Drug Deliv Transl Res 10:227–40.
  • Salem HF, Nafady MM, Ewees MGE, et al. (2021). Rosuvastatin calcium-based novel nanocubic vesicles capped with silver nanoparticles-loaded hydrogel for wound healing management: optimization employing Box-Behnken design, in vitro and in vivo assessment. J Liposome Res 11:1–17.
  • Scott LJ, Simpson D. (2007). Voriconazole : a review of its use in the management of invasive fungal infections. Drugs 67:269–98.
  • Singh NK, Lee DS. (2014). In situ gelling pH- and temperature-sensitive biodegradable block copolymer hydrogels for drug delivery. J Control Release 193:214–27.
  • Singh RM, Kumar A, Pathak K. (2013). Thermally triggered mucoadhesive in situ gel of loratadine: β-cyclodextrin complex for nasal delivery. AAPS PharmSciTech 14:412–24.
  • Somani SM, Husain K, Whitworth C, et al. (2000). Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats, Antioxidant defense system. Pharmacol Toxicol 86:234–41.
  • Srinivas P, Sreeja K. (2013). Formulation and evaluation of voriconazole loaded nanospongesfor oral and topical delivery. Int J Drug Dev Res 5:55–69.
  • Zhang H, Chen X, He JJ. (2009). Pharmacological action of clove oil and its application in oral care products. Oral Care Industry 19:23–4.
  • Zhu L, Ao J, Li P. (2015). A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation. Drug Des Devel Ther 29:3943–9.